The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

NEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine) ...

Not all children are eligible for the new Moderna COVID shots. Moderna, over the weekend, announced that the U.S. Food and Drug Administration had approved its second-generation COVID vaccine, but ...

Spikevax is now approved for all adults aged 65 years and older, and individuals aged 6 months through 64 years at increased risk for COVID-19 disease CAMBRIDGE, MA / ACCESS Newswire / July 10, 2025 / ...

June 2, 2025 -- The FDA has approved Moderna's new COVID-19 shot, an mRNA vaccine, with some limits on who can get it. The vaccine, called mNexspike, is for people who’ve previously received a ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and Novavax (NVAX) to trade lower on Tuesday, just as a major safety scare related ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. CHICAGO — The Food and Drug Administration has granted ...

The JN.1 Novavax vaccine is an alternative to the LP.8.1 Pfizer-BioNTech and Moderna vaccines that were rolled out in October ...

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

Neutralizing antibody levels rose 37-fold one month after the booster was given. Moderna announced Monday that its COVID-19 vaccine booster increases antibody levels against the omicron variant within ...

A young Black scientist shares her success story to encourage others. Sophia Upshaw was one of two Black participants in Moderna's first 45-person COVID-19 vaccination trial. Now, Upshaw is sharing ...